NASDAQ:AGIO
Agios Pharmaceuticals Stock News
$33.19
-1.15 (-3.35%)
At Close: May 20, 2024
– Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation – – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET – CAMBRIDGE, Mass., May 14,.
Agios to Present Updated Clinical Proof-of-Concept Data from the Phase — Study of Mitapivat ...
12:00am, Thursday, 14'th May 2020Agios Pharma To Present Updated Data From Phase 1 Study Of Vorasidenib In Non-Enhancing Glioma At ASCO May 29
09:27pm, Wednesday, 13'th May 2020
CAMBRIDGE, Mass., May 13, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
KPTI Has sNDAs In Process That Could More Than Double Its Share Price If Approved
02:54pm, Wednesday, 13'th May 2020
Xpovio's current label is 4th line Multiple Myeloma therapy (MM~6,000 patients/year). By 1/1/2021 Xpovio could be approved/labelled as 2nd/3rd line MM and 4th l
Will Agios Pharmaceuticals Continue to Surge Higher?
02:49pm, Wednesday, 13'th May 2020
As of late, it has definitely been a great time to be an investor Agios Pharmaceuticals
Stocks To Watch: Agios Pharmaceuticals Sees RS Rating Jump To 85
10:00pm, Tuesday, 12'th May 2020
On Tuesday, Agios Pharmaceuticals reached an important technical milestone, with its Relative Strength (RS) Rating entering into the 80-plus percentile with an upgrade to 85, up from 64 the day before
Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020
11:00am, Tuesday, 12'th May 2020
CAMBRIDGE, Mass., May 12, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies
Why Agios (AGIO) Stock Might be a Great Pick
02:18pm, Thursday, 07'th May 2020
Agios (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
JP Morgan Maintains Overweight on Agios Pharmaceuticals, Raises Price Target to $82
01:25pm, Monday, 04'th May 2020Analysts Are Upgrading Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Latest Results
12:14pm, Sunday, 03'rd May 2020
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) defied analyst predictions to release its quarterly results, which were...
Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat
01:57pm, Friday, 01'st May 2020
Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.
Brokers Are Upgrading Their Views On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) With These New Forecasts
12:10pm, Friday, 01'st May 2020
Shareholders in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) may be thrilled to learn that the analysts have just...
